
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
AtaiBeckley is a clinical-stage biopharmaceutical company with a strong pipeline of novel therapies for treatment-resistant depression (TRD) and social anxiety disorder. The company's Phase 2 trials have shown positive results, with a significant reduction in symptoms and a high percentage of responders and remission. With a fully funded research and development program and a leadership position in the short-acting psychedelics market, AtaiBeckley is well positioned to capture a significant share of the multi-billion dollar TRD market. Upcoming catalysts, including Phase 3 trial initiation and topline Phase 2 data, make AtaiBeckley a compelling investment opportunity.
Bears say
AtaiBeckley is facing challenges with their Phase 3 PARADIGM trial not meeting its primary endpoint of MADRS, but showed some improvement in those with EDS. Despite positive Phase 2b results for their BPL-003 drug, it is uncertain if the 25mg dose will continue to show improvements in the MADRS endpoint. With a completed enrollment of 585 participants for their upcoming Phase 3 CLARITY trial, the company is facing increased pressure to deliver positive results to justify the time and resources spent on their developing therapies.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares